| GlobalData, the industry analysis specialist's new | | | | 2.4 Drivers and Barriers for the Osteoarthritis |
| report, "Osteoarthritis – Drug Pipeline Analysis and | | | | Therapeutics Market 7 |
| Market Forecasts to 2016" is an essential source of | | | | 2.4.1 Drivers for the Osteoarthritis Therapeutics |
| information and analysis on the global osteoarthritis | | | | Market 7 |
| market. The report identifies the key trends shaping | | | | 2.4.2 Barriers for the Osteoarthritis Therapeutics |
| and driving the global osteoarthritis market. The | | | | Market 8 |
| report also provides insight on the prevalent | | | | 2.5 Opportunity and Unmet Need 8 |
| competitive landscape and the emerging players | | | | 2.6 Key Takeaway 9 |
| expected to bring significant shift in the market | | | | 3 Osteoarthirtis Market: Competitive Assessment 10 |
| positioning of the existing market leaders. Most | | | | 3.1 Overview 10 |
| importantly, the report provides valuable insight on | | | | 3.2 Strategic Competitor Assessment 10 |
| the pipeline products within the global osteoarthritis | | | | 3.3 Product Profiles of the Major Marketed Products |
| sector. | | | | in the Osteoarthritis Therapeutics Market 11 |
| This report is built using data and information sourced | | | | 3.3.1 Voltaren Gel 11 |
| from proprietary databases, primary and secondary | | | | 3.3.2 Celebrex 11 |
| research and in house analysis by GlobalData's team | | | | 3.3.3 Hyalgan 12 |
| of industry experts. | | | | 3.3.4 Mobic 12 |
| Scope | | | | 3.4 Key Takeaway 13 |
| The report analyzes market opportunities and | | | | 4 Osteoarthritis Market: Pipeline Assessment 14 |
| challenges for the global osteoarthritis market. Its | | | | 4.1 Overview 14 |
| scope includes | | | | 4.2 Strategic Pipeline Assessment 14 |
| - Annualized global osteoarthritis market revenues | | | | 4.2.1 Technology Trends Analytic Framework 14 |
| data from 2001 to 2009, forecast forward for 7 | | | | 4.3 Osteoarthritis Therapeutics – Promising Drugs |
| years to 2016. | | | | under Clinical Development 15 |
| - Geographies covered in this report include the US, | | | | 4.4 Molecule Profile for Promising Drugs under Clinical |
| the UK, Italy, Spain, Germany, France and Japan. | | | | Development 16 |
| - Pipeline analysis data providing a split across | | | | 4.4.1 SD6010 16 |
| different phases by mechanism of action being | | | | 4.4.2 PF-4383119 16 |
| developed and emerging trends. Key classes of | | | | 4.4.3 TDS-943 16 |
| mechanism of action include serotonin-norepinephrine | | | | 4.4.4 SMC021 17 |
| reuptake inhibitors, calcium homeostasis regulators, | | | | 4.4.5 CG5503 17 |
| and proton pump inhibitors, inhibitor of 5-lipoxygenase | | | | 4.4.6 Vicodin CR 18 |
| and cyclooxygenase, opioid receptor agonist, stem | | | | 4.5 Osteoarthritis Market – Clinical Pipeline by |
| cell therapy, cartilage cell synthesizer. | | | | Mechanism of Action 18 |
| - Analysis of the current and future market | | | | 4.6 Osteoarthritis Pipeline – Pipeline by Clinical |
| competition in the global osteoarthritis market. Key | | | | Phases of Development 19 |
| market players covered are Novartis AG, Pfizer, Inc., | | | | 4.6.1 Osteoarthritis Therapeutics – Phase III |
| Johnson & Johnson and Abbott Laboratories | | | | Clinical Pipeline 20 |
| - Insightful review of the key industry drivers, | | | | 4.6.2 Osteoarthritis Therapeutics – Phase II Clinical |
| restraints and challenges. Each trend is independently | | | | Pipeline 23 |
| researched to provide qualitative analysis of its | | | | 4.6.3 Osteoarthritis Therapeutics – Phase I Clinical |
| implications. | | | | Pipeline 25 |
| - Key topics covered include strategic competitor | | | | 4.6.4 Osteoarthritis Therapeutics – Discovery |
| assessment, market characterization, unmet needs | | | | Pipeline 26 |
| and implications for future market associated with | | | | 4.6.5 Osteoarthritis Therapeutics – Discontinued |
| osteoarthritis market. | | | | Pipeline 26 |
| Reasons to buy: | | | | 4.7 Key Takeaway 26 |
| The report will enhance your decision making | | | | 5 Osteoarthritis Market: Implications for Future |
| capability in a more rapid and time sensitive manner. | | | | Market Competition 27 |
| It will allow you to: | | | | 6 Osteoarthritis Market: Future Players in the |
| - Develop and design your in-licensing and out-licensing | | | | Osteoarthritis Market 28 |
| strategies through review of pipeline products and | | | | 6.1 Introduction 28 |
| technologies and by identifying companies with the | | | | 6.2 Novartis Pharma AG 28 |
| most robust pipeline. | | | | 6.2.1 Overview 28 |
| - Develop business strategies by understanding the | | | | 6.2.2 Osteoarthritis Disease Portfolio 29 |
| trends shaping and driving the global osteoarthritis | | | | 6.2.3 SMC021 29 |
| market. | | | | 6.3 Pfizer Inc. 29 |
| - Drive revenues by understanding key trends, | | | | 6.3.1 Overview 29 |
| innovative products and technologies, market | | | | 6.3.2 Osteoarthritis Disease Portfolio 30 |
| segments and companies likely to impact the global | | | | 6.3.3 SD6010 30 |
| osteoarthritis market in future. | | | | 6.3.4 PF-4383119 30 |
| - Formulate effective sales and marketing strategies | | | | 6.3.5 TDS-943 31 |
| by understanding the competitive landscape and by | | | | 6.4 Johnson and Johnson 31 |
| analyzing the performance of various competitors. | | | | 6.4.1 Company Overview 31 |
| - Identify emerging players with potentially strong | | | | 6.4.2 Osteoarthritis Disease Portfolio 32 |
| product portfolio and create effective | | | | 6.4.3 CG5503 32 |
| counter-strategies to gain competitive advantage. | | | | 6.5 Abbott Laboratories 32 |
| - Organize your sales and marketing efforts by | | | | 6.5.1 Company Overview 32 |
| identifying the market categories and segments that | | | | 6.5.2 Osteoarthritis Disease Portfolio 33 |
| present maximum opportunities for consolidations, | | | | 6.5.3 Vicodin CR 33 |
| investments and strategic partnerships. | | | | 7 Osteoarthritis Market: Appendix 34 |
| - What's the next big thing in the global osteoarthritis | | | | 7.1 Definitions 34 |
| market landscape? – Identify, understand and | | | | 7.2 Acronyms 34 |
| capitalize. | | | | 7.3 Research Methodology 34 |
| Table of contents | | | | 7.3.1 Coverage 35 |
| 1 Table of contents 2 | | | | 7.3.2 Secondary Research 35 |
| 1.1 List of Tables 4 | | | | 7.3.3 Forecasting 36 |
| 1.2 List of Figures 4 | | | | 7.3.4 Primary Research 38 |
| 2 Osteoarthritis Market: Market Characterization 5 | | | | 7.3.5 Expert Panel Validation 39 |
| 2.1 Overview 5 | | | | 7.4 Contact Us 39 |
| 2.2 Osteoarthritis Therapeutics Market Size 5 | | | | 7.5 Disclaimer 39 |
| 2.3 Osteoarthritis Market Forecast and CAGR 6 | | | | 7. |